论文部分内容阅读
用干扰素-α(IFN-α)治疗81例(男45例、女36例,中数年龄50.5岁,范围17～70岁)初诊的Ph染色体(Ph)阳性慢性粒细胞白血病(CML)慢性期患者。依Sokal’s分类将患者分为低危组(指数<0.8)39例,中危组(0.8<指数<1.2)32例和高危组(指数>1.2)10例。全部患者在确诊6个月内(中数时间45.5天)接受重组的IFN-α 5×10~6IU/sqm/d·sc。以后依血液学变化调整IFN-α剂量。血液学完全缓解(CHR)者,减量并调整至维持WBC1.5×10~9/L～5×10~9/L,血小板数50～150×10~9/(?)WBC<1.5×10~9/L或血小板数<50×10~9/L时停药。IFN-α分别治疗6个月、12个月未获CHR或细
Treatment of Ph Chromosome (Ph)-positive Chronic Myelogenous Leukemia (CML) in 81 Cases (45 males and 36 females, median age 50.5 years, range of 17 to 70 years) with interferon-alpha (IFN-alpha) Patients. According to Sokal’s classification, the patients were divided into low-risk group (index <0.8) 39 cases, moderate-risk group (0.8 1.2) 10 cases. All patients received recombinant IFN-α 5×10-6 IU/sqm/d·sc within 6 months of diagnosis (median 45.5 days). Afterwards, the dose of IFN-α was adjusted according to the hematological changes. Hematologic complete remission (CHR), reduced and adjusted to maintain WBC 1.5 × 10 ~ 9 / L ~ 5 × 10 ~ 9 / L, platelet count 50 ~ 150 × 10 ~ 9 / (?) WBC <1.5 × When 10~9/L or platelet count <50*10~9/L, the drug was discontinued. IFN-α was not CHR or fine for 6 months and 12 months, respectively